미국의 미생물학 및 세균 배양 배지 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 부문별 예측(2025-2030년)

U.S. Microbiology And Bacterial Culture Media Market Growth and Trends:

The U.S. microbiology and bacterial culture media market size is anticipated to reach USD 2.95 billion by 2030 and is anticipated to grow at a CAGR of 7.47% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to increasing demand for rapid diagnostics, rising prevalence of infectious diseases, expanding pharmaceutical and food testing applications, and continuous advancements in microbial culture technologies across clinical and industrial sectors.

The rising threat of antimicrobial resistance (AMR) has significantly increased the reliance on microbiology culture media for accurate identification of drug-resistant pathogens. As pathogens evolve resistance to conventional antibiotics, precise microbial detection becomes critical to guide effective treatment strategies. This growing awareness has spurred intensified research and development efforts aimed at combating AMR, fueling demand for advanced bacterial culture media. Consequently, microbiology culture remains a vital tool in pharmaceutical development, infection control, and clinical diagnostics, thus propelling the market growth across the region.

In addition, Continuous technological advancements in culture techniques, including automated systems and sophisticated identification methods, have revolutionized microbiology laboratories. These innovations streamline workflows, reduce manual errors, and significantly improve the accuracy and speed of microbial detection. Enhanced efficiency in sample processing and data analysis enables laboratories to meet growing demands for rapid and reliable results. Furthermore, these improvements support regulatory compliance and quality assurance in pharmaceutical, clinical, and research settings. Collectively, such advancements drive increased adoption of culture media, thereby stimulating sustained growth and competitiveness in the microbiology market.

However, the high costs associated with advanced equipment and culture media limit adoption, especially among smaller laboratories and in emerging markets. Additionally, the complexity of some automated systems requires specialized training, which can be a barrier to implementation. Furthermore, contamination risks and the need for precise environmental controls remain persistent, potentially impacting test reliability and overall operational efficiency.

U.S. Microbiology And Bacterial Culture Media Market Report Highlights:

• The dehydrated culture media held the largest revenue share in 2024, owing to its long shelf life and ease of storage. Additionally, its cost-effectiveness and convenience in preparation make it the preferred choice for many laboratories. The ready-to-use media segment is expected to grow at the fastest CAGR over the forecast period.
• The pharmaceutical & biopharmaceutical production segment dominated the application segment with the largest revenue share of 38.13% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period. This is driven by increased demand for vaccines and biologics. Stringent regulatory requirements for quality and safety testing further propel its growth. However,diagnostics are expected to grow significantly over the forecast period.
• In October 2024, the U.S. Pharmacopeia (USP) announced its acquisition of Stratix Labs, a microbiology technology company headquartered in Saint Paul, MN. This strategic move represents a significant advancement for USP's portfolio, enhancing its microbiological solutions to support microbial contamination control across various pharmaceutical applications, including biologics and compounded medications.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growth in global food microbiology testing
    • 3.2.1.2. Rising need for high-quality culture media for diagnostic applications
    • 3.2.1.3. Continuous advancements in biopharmaceutical manufacturing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of advanced or specialty media
    • 3.2.2.2. Growing preference for alternative methods like molecular diagnostics
• 3.3. U.S. Microbiology & Bacterial Culture Media Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Microbiology & Bacterial Culture Media Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. U.S. Microbiology & Bacterial Culture Media Market Product Movement Analysis
• 4.3. U.S. Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Dehydrated Culture Media
  • 4.4.1. Dehydrated Culture Media Market, 2018 - 2030 (USD Million)
• 4.5. Ready-to-use Media
  • 4.5.1. Ready-to-use Media Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Microbiology & Bacterial Culture Meida Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. U.S. Microbiology & Bacterial Culture Media Market Application Movement Analysis
• 5.3. U.S. Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Food & Water Testing
  • 5.4.1. Food & Water Testing Market, 2018 - 2030 (USD Million)
  • 5.4.2. Food
    • 5.4.2.1. Food Market, 2018 - 2030 (USD Million)
  • 5.4.3. Animal Feed
    • 5.4.3.1. Animal Feed Market, 2018 - 2030 (USD Million)
  • 5.4.4. Water Testing
    • 5.4.4.1. Water Testing Market, 2018 - 2030 (USD Million)
• 5.5. Diagnostics
  • 5.5.1. Diagnostics Market, 2018 - 2030 (USD Million)
• 5.6. Pharmaceutical & Biopharmaceutical Production
  • 5.6.1. Pharmaceutical & Biopharmaceutical Production Market, 2018 - 2030 (USD Million)
• 5.7. Bioenergy & Agricultural Research
  • 5.7.1. Bioenergy & Agricultural Research Market, 2018 - 2030 (USD Million)
• 5.8. Cosmetics and Personal Care Applications
  • 5.8.1. Cosmetics and Personal Care Applications Market, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Strategy Mapping
• 6.3. Company Profiles/Listing
  • 6.3.1. Thermo Fisher Scientific, Inc.
    • 6.3.1.1. Overview
    • 6.3.1.2. Financial Performance
    • 6.3.1.3. Product Benchmarking
    • 6.3.1.4. Strategic Initiatives
  • 6.3.2. Merck KGaA
    • 6.3.2.1. Overview
    • 6.3.2.2. Financial Performance
    • 6.3.2.3. Product Benchmarking
    • 6.3.2.4. Strategic Initiatives
  • 6.3.3. bioMerieux SA
    • 6.3.3.1. Overview
    • 6.3.3.2. Financial Performance
    • 6.3.3.3. Product Benchmarking
    • 6.3.3.4. Strategic Initiatives
  • 6.3.4. HiMedia Laboratories
    • 6.3.4.1. Overview
    • 6.3.4.2. Financial Performance
    • 6.3.4.3. Product Benchmarking
    • 6.3.4.4. Strategic Initiatives
  • 6.3.5. BD
    • 6.3.5.1. Overview
    • 6.3.5.2. Financial Performance
    • 6.3.5.3. Product Benchmarking
    • 6.3.5.4. Strategic Initiatives
  • 6.3.6. Neogen Corporation
    • 6.3.6.1. Overview
    • 6.3.6.2. Financial Performance
    • 6.3.6.3. Product Benchmarking
    • 6.3.6.4. Strategic Initiatives
  • 6.3.7. Bio-Rad Laboratories, Inc.
    • 6.3.7.1. Overview
    • 6.3.7.2. Financial Performance
    • 6.3.7.3. Product Benchmarking
    • 6.3.7.4. Strategic Initiatives
  • 6.3.8. SHIMADZU
    • 6.3.8.1. Overview
    • 6.3.8.2. Financial Performance
    • 6.3.8.3. Product Benchmarking
    • 6.3.8.4. Strategic Initiatives
  • 6.3.9. Hardy Diagnostics
    • 6.3.9.1. Overview
    • 6.3.9.2. Financial Performance
    • 6.3.9.3. Product Benchmarking
    • 6.3.9.4. Strategic Initiatives
  • 6.3.10. Alpha Teknova, Inc.
    • 6.3.10.1. Overview
    • 6.3.10.2. Financial Performance
    • 6.3.10.3. Product Benchmarking
    • 6.3.10.4. Strategic Initiatives
  • 6.3.11. MP Biomedicals
    • 6.3.11.1. Overview
    • 6.3.11.2. Financial Performance
    • 6.3.11.3. Product Benchmarking
    • 6.3.11.4. Strategic Initiatives